ASTROTECH ANNOUNCES CONFIRMED AGLAB, INC. FIELD TRIAL RESULTS
09 Maio 2023 - 9:00AM
Astrotech Corporation (NASDAQ: ASTC) (the “Company”), is announcing
today that its subsidiary, AgLAB, Inc., confirmed the results from
field trials using the AgLAB 1000-D2TM mass spectrometer and the
Maximum Value ProcessTM testing method (“AgLAB MVP”). AgLAB MVP is
designed to improve yields and bottom-line profits for hemp (CBD)
and cannabis (THC) producers of distilled oils.
Large scale CBD and THC oil processors use molecular
distillation systems (“MDS”) to produce the valuable oils that are
used in lotions, pills, tinctures, and cartridges. Using the AgLAB
MVP solution, customers are now able to analyze the oils during
processing and make near real-time adjustments that can boost the
ending-weight yields and potencies.
“The AgLAB 1000 is a powerful tool for large-scale distillers.
This product and method fill a void by providing an easy and
accurate real-time analysis that is used to make the right
adjustments and improve the yields,” said Joe Levinthal, Chief
Science Officer and Master Distiller of AgLAB.
“After hundreds of field sample tests, we are excited to
announce the results using the AgLAB 1000-D2 mass spectrometer and
the MVP testing method, which we believe demonstrate how valuable
this tool can be for large-scale cannabis and hemp oil processors.
During our field trials, we were able to improve ending-weight
yields by an average of 30%, increasing customer profitability,”
stated Thomas B. Pickens III, CEO and CTO of Astrotech.
About the AgLAB 1000™
and the BreathTest-1000™
This press release contains information about our new products
under development, AgLAB 1000 and BreathTest-1000. Product
development involves a high degree of risk and uncertainty, and
there can be no assurance that our new products will be
successfully developed, achieve their intended benefits, receive
full market authorization, or be commercially successful. In
addition, FDA approval will be required to market BreathTest-1000
in the United States. Obtaining FDA approval is a complex and
lengthy process, and there can be no assurance that FDA approval
for BreathTest-1000 will be granted on a timely basis or at
all.
About Astrotech Corporation
Astrotech (Nasdaq: ASTC) is a mass spectrometry company that
launches, manages, and commercializes scalable companies based on
its innovative core technology through its wholly-owned
subsidiaries. 1st
Detect develops, manufactures, and sells trace
detectors for use in the security and detection market.
AgLAB develops and sells chemical analyzers for
use in the agriculture market. BreathTech is
developing a breath analysis tool to screen for volatile organic
compounds that that could indicate infections or critical
conditions. Astrotech is headquartered in Austin, Texas. For
information, please visit www.astrotechcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the Safe Harbor provisions of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements are subject to risks, trends, and uncertainties that
could cause actual results to be materially different from the
forward-looking statement. These factors include, but are not
limited to, the adverse impact of recent inflationary pressures,
including significant increases in fuel costs, global economic
conditions and events related to these conditions, including the
ongoing war in Ukraine and the COVID-19 pandemic, the Company’s use
of proceeds from the common stock offerings, whether we can
successfully complete the development of our new products and
proprietary technologies, whether we can obtain the FDA and other
regulatory approvals required to market our products under
development in the United States or abroad, whether the market will
accept our products and services and whether we are successful in
identifying, completing and integrating acquisitions, as well as
other risk factors and business considerations described in the
Company’s Securities and Exchange Commission filings including the
Company’s most recent Annual Report on Form 10-K. Any
forward-looking statements in this document should be evaluated in
light of these important risk factors. Although the Company
believes the expectations reflected in its forward-looking
statements are reasonable and are based on reasonable assumptions,
no assurance can be given that these assumptions are accurate or
that any of these expectations will be achieved (in full or at all)
or will prove to have been correct. Moreover, such statements are
subject to a number of assumptions, risks and uncertainties, many
of which are beyond the control of the Company, which may cause
actual results to differ materially from those implied or expressed
by the forward-looking statements. In addition, any forward-looking
statements included in this press release represent the Company’s
views only as of the date of its publication and should not be
relied upon as representing its views as of any subsequent date.
The Company assumes no obligation to correct or update these
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by applicable
law.
Jaime Hinojosa, Chief Financial Officer, Astrotech Corporation, (512) 485-9530
Astrotech (NASDAQ:ASTC)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Astrotech (NASDAQ:ASTC)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025